Therapy for myeloproliferative neoplasms: When, which agent, and how?

Holly L. Geyer, Ruben A. Mesa

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

Myeloproliferative neoplasms, including polycythemia vera (PV), essential thrombocythemia, and myelofibrosis (MF) (both primary and secondary), are recognized for their burdensome symptom profiles, life-threatening complications, and risk of progression to acute leukemia. Recent advancements in our ability to diagnose and prognosticate these clonal malignancies have paralleled the development of MPN-targeted therapies that have had a significant impact on disease burden and quality of life. Ruxolitinib has shown success in alleviating thesymptomatic burden, reducing splenomegaly and improving quality of life in patients with MF. The role and clinical expectations of JAK2 inhibition continues to expand to a variety of investigational arenas. Clinical trials for patients with MF focus on new JAK inhibitors with potentially less myelosuppression(pacritinib) or even activity for anemia (momelotinib). Further efforts focus on combinationtrials (including a JAK inhibitor base) or targeting new pathways (ie, telomerase). Similarly, therapy for PV continues to evolve with phase 3 trials investigating optimal frontline therapy (hydroxyurea or IFN) and second-line therapy for hydroxyurea-refractory or intolerant PV with JAK inhibitors. In this chapter, we review the evolving data and role of JAK inhibition (alone or in combination) in the management of patients with MPNs.

Original languageEnglish (US)
Pages (from-to)3529-3537
Number of pages9
JournalBlood
Volume124
Issue number24
DOIs
StatePublished - Dec 4 2014

Fingerprint

Hydroxyurea
Polycythemia Vera
Primary Myelofibrosis
Telomerase
Refractory materials
Neoplasms
Quality of Life
Essential Thrombocythemia
Splenomegaly
Therapeutics
Anemia
Leukemia
Clinical Trials
N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide
INCB018424
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Therapy for myeloproliferative neoplasms : When, which agent, and how? / Geyer, Holly L.; Mesa, Ruben A.

In: Blood, Vol. 124, No. 24, 04.12.2014, p. 3529-3537.

Research output: Contribution to journalArticle

Geyer, Holly L. ; Mesa, Ruben A. / Therapy for myeloproliferative neoplasms : When, which agent, and how?. In: Blood. 2014 ; Vol. 124, No. 24. pp. 3529-3537.
@article{3a1ae2d673e745d0849d498e37ce7879,
title = "Therapy for myeloproliferative neoplasms: When, which agent, and how?",
abstract = "Myeloproliferative neoplasms, including polycythemia vera (PV), essential thrombocythemia, and myelofibrosis (MF) (both primary and secondary), are recognized for their burdensome symptom profiles, life-threatening complications, and risk of progression to acute leukemia. Recent advancements in our ability to diagnose and prognosticate these clonal malignancies have paralleled the development of MPN-targeted therapies that have had a significant impact on disease burden and quality of life. Ruxolitinib has shown success in alleviating thesymptomatic burden, reducing splenomegaly and improving quality of life in patients with MF. The role and clinical expectations of JAK2 inhibition continues to expand to a variety of investigational arenas. Clinical trials for patients with MF focus on new JAK inhibitors with potentially less myelosuppression(pacritinib) or even activity for anemia (momelotinib). Further efforts focus on combinationtrials (including a JAK inhibitor base) or targeting new pathways (ie, telomerase). Similarly, therapy for PV continues to evolve with phase 3 trials investigating optimal frontline therapy (hydroxyurea or IFN) and second-line therapy for hydroxyurea-refractory or intolerant PV with JAK inhibitors. In this chapter, we review the evolving data and role of JAK inhibition (alone or in combination) in the management of patients with MPNs.",
author = "Geyer, {Holly L.} and Mesa, {Ruben A.}",
year = "2014",
month = "12",
day = "4",
doi = "10.1182/blood-2014-05-577635",
language = "English (US)",
volume = "124",
pages = "3529--3537",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "24",

}

TY - JOUR

T1 - Therapy for myeloproliferative neoplasms

T2 - When, which agent, and how?

AU - Geyer, Holly L.

AU - Mesa, Ruben A.

PY - 2014/12/4

Y1 - 2014/12/4

N2 - Myeloproliferative neoplasms, including polycythemia vera (PV), essential thrombocythemia, and myelofibrosis (MF) (both primary and secondary), are recognized for their burdensome symptom profiles, life-threatening complications, and risk of progression to acute leukemia. Recent advancements in our ability to diagnose and prognosticate these clonal malignancies have paralleled the development of MPN-targeted therapies that have had a significant impact on disease burden and quality of life. Ruxolitinib has shown success in alleviating thesymptomatic burden, reducing splenomegaly and improving quality of life in patients with MF. The role and clinical expectations of JAK2 inhibition continues to expand to a variety of investigational arenas. Clinical trials for patients with MF focus on new JAK inhibitors with potentially less myelosuppression(pacritinib) or even activity for anemia (momelotinib). Further efforts focus on combinationtrials (including a JAK inhibitor base) or targeting new pathways (ie, telomerase). Similarly, therapy for PV continues to evolve with phase 3 trials investigating optimal frontline therapy (hydroxyurea or IFN) and second-line therapy for hydroxyurea-refractory or intolerant PV with JAK inhibitors. In this chapter, we review the evolving data and role of JAK inhibition (alone or in combination) in the management of patients with MPNs.

AB - Myeloproliferative neoplasms, including polycythemia vera (PV), essential thrombocythemia, and myelofibrosis (MF) (both primary and secondary), are recognized for their burdensome symptom profiles, life-threatening complications, and risk of progression to acute leukemia. Recent advancements in our ability to diagnose and prognosticate these clonal malignancies have paralleled the development of MPN-targeted therapies that have had a significant impact on disease burden and quality of life. Ruxolitinib has shown success in alleviating thesymptomatic burden, reducing splenomegaly and improving quality of life in patients with MF. The role and clinical expectations of JAK2 inhibition continues to expand to a variety of investigational arenas. Clinical trials for patients with MF focus on new JAK inhibitors with potentially less myelosuppression(pacritinib) or even activity for anemia (momelotinib). Further efforts focus on combinationtrials (including a JAK inhibitor base) or targeting new pathways (ie, telomerase). Similarly, therapy for PV continues to evolve with phase 3 trials investigating optimal frontline therapy (hydroxyurea or IFN) and second-line therapy for hydroxyurea-refractory or intolerant PV with JAK inhibitors. In this chapter, we review the evolving data and role of JAK inhibition (alone or in combination) in the management of patients with MPNs.

UR - http://www.scopus.com/inward/record.url?scp=84916201113&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84916201113&partnerID=8YFLogxK

U2 - 10.1182/blood-2014-05-577635

DO - 10.1182/blood-2014-05-577635

M3 - Article

C2 - 25472969

AN - SCOPUS:84916201113

VL - 124

SP - 3529

EP - 3537

JO - Blood

JF - Blood

SN - 0006-4971

IS - 24

ER -